With this systematic review and meta-analysis, we set out to clarify the type, incidence, and relative risk of CVAEs in patients with melanoma who are being treated with a combination of BRAF and MEK inhibitors compared with patients receiving BRAF inhibitor monotherapy. Here, MAP2K7 is linked to melanoma.